26682-82-6

Upstream product

• 137182-68-4 4-ethylidenecyclohexanone ethylene acetal 
• 860545-42-2 3-vinylpentane-1,3,5-trinitrile 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 113124-21-3 4-ethylcyclohexanone diethyl acetal 
• 1422253-45-9 (E)-4-ethylidene-ε-caprolactone 
• 1400634-14-1 C₂₃H₂₈F₆N₂O 
• 1400634-15-2 C₂₆H₃₆F₃N₃O*ClH 
• 161791-83-9 2-(2-Bromo-allyl)-4-eth-(Z)-ylidene-cyclohexanone 
• 137182-69-5 1-ethylidene-4-hexadecyl-4-hydroxycyclohexane 
• 160803-47-4 2-(2-Bromo-1-hydroxy-allyl)-4-eth-(E)-ylidene-cyclohexanone 

Relevant academic research and scientific papers

A new type of stereoselectivity in Baeyer-Villiger reactions: Access to E- and Z-olefins

A new concept for accessing configurationally defined trisubstituted olefins has been developed. Starting from a common ketone precursor of the type 4-ethylidenecyclohexanone, Baeyer-Villiger monooxygenases are employed as catalysts in diastereoselective Baeyer-Villiger reactions leading to the corresponding E- or Z-configurated lactones. Wild-type cyclohexanone monooxygenase (CHMO) as catalyst delivers the E-isomers and a directed evolution mutant the opposite Z-isomers. Subsequent transition metal-catalyzed chemical transformations of a key product containing a vinyl bromide moiety provide a variety of different trisubstituted E- or Z-olefins. A model based on QM/MM sheds light on the origin of this unusual type of diastereoselectivity. In contrast to this biocatalytic approach, traditional Baeyer-Villiger reagents such as m-CPBA fail to show any selectivity, 1:1 mixtures of E- and Z-olefins being formed. Copyright

Spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and AP-1 inhibitors containing the same

The spiro compounds of the present invention represented by the general formula: wherein A, R2, R3, R4, R5, R6and n are as defined in the specification, exhibit an AP-1 activity inhibitory action and, based on the AP-1 inhibitory action, suppresses the expression of a wide variety of genes and are useful as an agent for treating and preventing autoimmune diseases with lessoned side reactions.

A convenient synthesis of some 1,4-disubstituted 7-oxabicyclo[2.2.1]heptanes

An efficient synthesis of a 1,4-disubstituted 7-oxabicyclo[2.2.1]heptane intermediate and its subsequent conversion to a potential PAF antagonist is described.